Abstract
To assess the value of one week preoperative subconjunctival injection of bevacizumab on the surgical management of primary pterygia and also to evaluate the rate of recurrence after excision. This is experimental clinical trial included110 eyes of 110 patients (59 males and 51 females) with a mean age of (49.62 ± 16.54 years), range (27–68) had primary pterygia. The dose of bevacizumab was a 1.25 mg (0.05 ml) one week before pterygium surgery. Surgery was done using excision with direct conjunctival suturing technique. All pterygia were followed up for 6 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Indian Journal of Public Health Research & Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
